Reference : Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal...
Scientific journals : Article
Life sciences : Veterinary medicine & animal health
Human health sciences : Laboratory medicine & medical technology
Human health sciences : Immunology & infectious disease
Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD
Gogev, S. [> > > >]
Vanderheijden, N. [> > > >]
Lemaire, Mylène [ > > ]
Schynts, F. [> > > >]
D'Offay, J. [> > > >]
Deprez, I. [> > > >]
Adam, Martine [Centre Hospitalier Universitaire de Liège - CHU > > Ophtalmologie >]
Eloit, M. [> > > >]
Thiry, Etienne mailto [Université de Liège - ULiège > Département des maladies infectieuses et parasitaires > Virologie, épidémiologie et pathologie des maladies virales >]
Elsevier Sci Ltd
Yes (verified by ORBi)
[en] BHV-1 ; glycoprotein D ; recombinant human adenovirus type 5
[en] Replication-defective human adenoviruses type 5 (HAd5) expressing the bovine herpesvirus type 1 (BHV-1) glycoprotein gC or gD under the control of the human cytomegalovirus immediate-early promoter/enhancer (AdCMVgC or AdCMVgD) or the 5' regulatory region of the human desmin gene (AdDESMgC or AdDESMgD) were generated. A preliminary experiment performed on rabbits showed that the intranasal administration of AdCMV elicited higher levels of BHV-1 neutralizing antibodies than the intramuscular administration of AdDESM. The obtained results allowed to select the replication-defective AdCMVgC and AdCMVgD for further assessment of their potential as a recombinant vaccine in cattle. Calves were injected intranasally twice 3 weeks apart with either AdCMVgC or AdCMVgD or a combination of these two recombinants or a commercially available live vaccine for comparison. The highest BHV-1 neutralizing antibody titres were obtained with AdCMVgD followed by the live vaccine and to a lower extent with the combination of the two recombinants (AdCMVgC+AdCMVgD). Calves were protected against intranasal BHV-1 challenge performed 3 weeks after the second immunization. In view of the obtained results, recombinant HAd5 may be developed as an intranasal vaccine vector in cattle administrated either alone or sequentially with non-human adenovirus-based vectors.

File(s) associated to this reference

Fulltext file(s):

Restricted access
198pub_thiry.pdfAuthor postprint233.22 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.